AU2017234319B2 - Novel polysaccharide-protein conjugates and process to obtain thereof - Google Patents

Novel polysaccharide-protein conjugates and process to obtain thereof Download PDF

Info

Publication number
AU2017234319B2
AU2017234319B2 AU2017234319A AU2017234319A AU2017234319B2 AU 2017234319 B2 AU2017234319 B2 AU 2017234319B2 AU 2017234319 A AU2017234319 A AU 2017234319A AU 2017234319 A AU2017234319 A AU 2017234319A AU 2017234319 B2 AU2017234319 B2 AU 2017234319B2
Authority
AU
Australia
Prior art keywords
polysaccharide
conjugates
protein
protein conjugates
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017234319A
Other languages
English (en)
Other versions
AU2017234319A1 (en
Inventor
Manoj Kumar CHHIKARA
Juned DALAL
Davinder Gill
Rakesh RANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Original Assignee
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of AU2017234319A1 publication Critical patent/AU2017234319A1/en
Application granted granted Critical
Publication of AU2017234319B2 publication Critical patent/AU2017234319B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2017234319A 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof Expired - Fee Related AU2017234319B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201611008901 2016-03-15
IN201611008901 2016-03-15
PCT/IB2017/051408 WO2017158480A1 (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Publications (2)

Publication Number Publication Date
AU2017234319A1 AU2017234319A1 (en) 2018-09-27
AU2017234319B2 true AU2017234319B2 (en) 2021-11-04

Family

ID=59851687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017234319A Expired - Fee Related AU2017234319B2 (en) 2016-03-15 2017-03-10 Novel polysaccharide-protein conjugates and process to obtain thereof

Country Status (9)

Country Link
JP (1) JP2019508468A (zh)
KR (1) KR102428253B1 (zh)
CN (1) CN108883192A (zh)
AU (1) AU2017234319B2 (zh)
BR (1) BR112018068523A2 (zh)
MX (1) MX2018010920A (zh)
RU (1) RU2758090C2 (zh)
WO (1) WO2017158480A1 (zh)
ZA (1) ZA201806043B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
JP2020525495A (ja) * 2017-06-27 2020-08-27 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
CN110652585B (zh) * 2018-10-26 2023-05-26 武汉博沃生物科技有限公司 多糖-蛋白缀合物免疫制剂及其制备与应用
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US20150044253A1 (en) * 2005-06-27 2015-02-12 Glaxosmithkline Biologicals S.A. Immunogenic composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
RU2233172C2 (ru) * 1997-07-17 2004-07-27 Бакстэ Хелскеа С.А. Иммуногенный коньюгат полисахарид h. influenzae - порин менингококка группы b (варианты), способ его получения, фармацевтическая композиция и способ индукции иммунного ответа у животного в отношении h.influenzae
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
MX354103B (es) * 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044253A1 (en) * 2005-06-27 2015-02-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions

Also Published As

Publication number Publication date
RU2758090C2 (ru) 2021-10-26
CN108883192A (zh) 2018-11-23
KR20180121564A (ko) 2018-11-07
ZA201806043B (en) 2019-05-29
RU2018135066A (ru) 2020-04-06
WO2017158480A1 (en) 2017-09-21
MX2018010920A (es) 2019-03-06
AU2017234319A1 (en) 2018-09-27
KR102428253B1 (ko) 2022-08-02
RU2018135066A3 (zh) 2020-11-10
BR112018068523A2 (pt) 2019-01-22
JP2019508468A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
AU2017234319B2 (en) Novel polysaccharide-protein conjugates and process to obtain thereof
JP5361767B2 (ja) 水中において改善された安定性を持つ修飾糖
CN111065387B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN111093650B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
ES2658851T3 (es) Vacunas de matriz de proteína y métodos de preparación y administración de tales vacunas
ES2635488T3 (es) Sacáridos modificados
CN117736348A (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
TW201925458A (zh) 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
KR101266552B1 (ko) 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
CN105828839B (zh) 沙门氏菌缀合物疫苗
JP7100031B2 (ja) 免疫原性コンジュゲート及びその使用
JP2021001182A (ja) ナイセリア・メニンギティディスのワクチン
ES2293002T5 (es) Vacunas de polisacárido y glucoconjugado mejoradas
US20110229513A1 (en) LPS Based Vaccines
WO2019198096A1 (en) Tetravalent meningococcal vaccine composition and process to prepare thereof

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee